Imatinib provides lasting treatment for patients with advanced GISTs.
D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001549:Benzamides; D017322:Clinical Trials, Phase II as Topic; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D000068877:Imatinib Mesylate; D015337:Multicenter Studies as Topic; D010879:Piperazines / Q000494:pharmacology*; D011379:Prognosis; D011743:Pyrimidines / Q000494:pharmacology*; D017154:Stromal Cells; D013534:Survival; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate